nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.105	0.137	CbGbCtD
Methylnaltrexone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0989	0.129	CbGbCtD
Methylnaltrexone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0989	0.129	CbGbCtD
Methylnaltrexone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0895	0.116	CbGbCtD
Methylnaltrexone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0895	0.116	CbGbCtD
Methylnaltrexone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0772	0.1	CbGbCtD
Methylnaltrexone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.075	0.0974	CbGbCtD
Methylnaltrexone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0678	0.0881	CbGbCtD
Methylnaltrexone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0678	0.0881	CbGbCtD
Methylnaltrexone—Flatulence—Amprenavir—acquired immunodeficiency syndrome	0.0023	0.0122	CcSEcCtD
Methylnaltrexone—Flatulence—Didanosine—acquired immunodeficiency syndrome	0.0021	0.0111	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00197	0.0105	CcSEcCtD
Methylnaltrexone—Erythema—Nevirapine—acquired immunodeficiency syndrome	0.00191	0.0101	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00187	0.00989	CcSEcCtD
Methylnaltrexone—Erythema—Nelfinavir—acquired immunodeficiency syndrome	0.00185	0.00981	CcSEcCtD
Methylnaltrexone—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00185	0.0098	CcSEcCtD
Methylnaltrexone—Flatulence—Nelfinavir—acquired immunodeficiency syndrome	0.00182	0.00967	CcSEcCtD
Methylnaltrexone—Flatulence—Stavudine—acquired immunodeficiency syndrome	0.00182	0.00964	CcSEcCtD
Methylnaltrexone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00172	0.263	CbGeAlD
Methylnaltrexone—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00164	0.00871	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00162	0.00857	CcSEcCtD
Methylnaltrexone—Erythema—Zidovudine—acquired immunodeficiency syndrome	0.0016	0.0085	CcSEcCtD
Methylnaltrexone—Flatulence—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.00838	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00157	0.0083	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00156	0.00827	CcSEcCtD
Methylnaltrexone—Oedema—Nevirapine—acquired immunodeficiency syndrome	0.00156	0.00827	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.00156	0.00825	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.00154	0.00815	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00153	0.00811	CcSEcCtD
Methylnaltrexone—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00152	0.00803	CcSEcCtD
Methylnaltrexone—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.00151	0.00801	CcSEcCtD
Methylnaltrexone—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.0015	0.00797	CcSEcCtD
Methylnaltrexone—Oedema—Abacavir—acquired immunodeficiency syndrome	0.00148	0.00787	CcSEcCtD
Methylnaltrexone—Pain—Didanosine—acquired immunodeficiency syndrome	0.00148	0.00786	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00148	0.00783	CcSEcCtD
Methylnaltrexone—Flatulence—Indinavir—acquired immunodeficiency syndrome	0.00147	0.00779	CcSEcCtD
Methylnaltrexone—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00147	0.00778	CcSEcCtD
Methylnaltrexone—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00775	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.00146	0.00774	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00772	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00146	0.00771	CcSEcCtD
Methylnaltrexone—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00144	0.00764	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.00142	0.00752	CcSEcCtD
Methylnaltrexone—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.00141	0.00747	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00139	0.0397	CbGpPWpGaD
Methylnaltrexone—Flatulence—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.00736	CcSEcCtD
Methylnaltrexone—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00137	0.00727	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00136	0.00719	CcSEcCtD
Methylnaltrexone—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.00135	0.00715	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00135	0.00714	CcSEcCtD
Methylnaltrexone—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00133	0.00707	CcSEcCtD
Methylnaltrexone—Flatulence—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00704	CcSEcCtD
Methylnaltrexone—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.00131	0.00694	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.0013	0.00691	CcSEcCtD
Methylnaltrexone—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.0013	0.0069	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.0013	0.00689	CcSEcCtD
Methylnaltrexone—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00685	CcSEcCtD
Methylnaltrexone—Pain—Stavudine—acquired immunodeficiency syndrome	0.00129	0.00683	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00128	0.00681	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.00128	0.00679	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.00128	0.00676	CcSEcCtD
Methylnaltrexone—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00674	CcSEcCtD
Methylnaltrexone—Pain—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00673	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00671	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00126	0.00669	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00124	0.00655	CcSEcCtD
Methylnaltrexone—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00123	0.00654	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00123	0.00653	CcSEcCtD
Methylnaltrexone—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00651	CcSEcCtD
Methylnaltrexone—Oedema—Indinavir—acquired immunodeficiency syndrome	0.00122	0.00645	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.00121	0.00643	CcSEcCtD
Methylnaltrexone—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00121	0.00641	CcSEcCtD
Methylnaltrexone—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.0012	0.00636	CcSEcCtD
Methylnaltrexone—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00119	0.00633	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00119	0.00633	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00119	0.00632	CcSEcCtD
Methylnaltrexone—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00119	0.00631	CcSEcCtD
Methylnaltrexone—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00119	0.00629	CcSEcCtD
Methylnaltrexone—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.00118	0.00627	CcSEcCtD
Methylnaltrexone—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00627	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00624	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00118	0.0336	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00117	0.00622	CcSEcCtD
Methylnaltrexone—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00115	0.00607	CcSEcCtD
Methylnaltrexone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00113	0.00599	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00113	0.00599	CcSEcCtD
Methylnaltrexone—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.00598	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00113	0.00598	CcSEcCtD
Methylnaltrexone—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00593	CcSEcCtD
Methylnaltrexone—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00112	0.00592	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00111	0.00589	CcSEcCtD
Methylnaltrexone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.0011	0.00585	CcSEcCtD
Methylnaltrexone—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.0011	0.00583	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00108	0.0308	CbGpPWpGaD
Methylnaltrexone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00107	0.00567	CcSEcCtD
Methylnaltrexone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00567	CcSEcCtD
Methylnaltrexone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00107	0.00566	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00106	0.00564	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00105	0.00559	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00105	0.00557	CcSEcCtD
Methylnaltrexone—Pain—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00552	CcSEcCtD
Methylnaltrexone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00104	0.00549	CcSEcCtD
Methylnaltrexone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00103	0.00548	CcSEcCtD
Methylnaltrexone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00103	0.00546	CcSEcCtD
Methylnaltrexone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00103	0.00546	CcSEcCtD
Methylnaltrexone—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00539	CcSEcCtD
Methylnaltrexone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00102	0.00538	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00102	0.00538	CcSEcCtD
Methylnaltrexone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000999	0.0053	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000998	0.00529	CcSEcCtD
Methylnaltrexone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000996	0.00528	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000996	0.00528	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000993	0.00526	CcSEcCtD
Methylnaltrexone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000992	0.00526	CcSEcCtD
Methylnaltrexone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000989	0.00524	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000984	0.00522	CcSEcCtD
Methylnaltrexone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000984	0.00521	CcSEcCtD
Methylnaltrexone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000981	0.0052	CcSEcCtD
Methylnaltrexone—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00098	0.00519	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000968	0.00513	CcSEcCtD
Methylnaltrexone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000963	0.0051	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000961	0.00509	CcSEcCtD
Methylnaltrexone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000961	0.00509	CcSEcCtD
Methylnaltrexone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000958	0.00508	CcSEcCtD
Methylnaltrexone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000952	0.00504	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00095	0.00504	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000947	0.00502	CcSEcCtD
Methylnaltrexone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000944	0.005	CcSEcCtD
Methylnaltrexone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000941	0.00499	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000941	0.00499	CcSEcCtD
Methylnaltrexone—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000935	0.00495	CcSEcCtD
Methylnaltrexone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000927	0.00491	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000917	0.00486	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000912	0.0261	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00091	0.00482	CcSEcCtD
Methylnaltrexone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000908	0.00481	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000904	0.00479	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.0009	0.00477	CcSEcCtD
Methylnaltrexone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000898	0.00476	CcSEcCtD
Methylnaltrexone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000896	0.00475	CcSEcCtD
Methylnaltrexone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000895	0.00474	CcSEcCtD
Methylnaltrexone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000882	0.00467	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000879	0.00466	CcSEcCtD
Methylnaltrexone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000871	0.00461	CcSEcCtD
Methylnaltrexone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00087	0.00461	CcSEcCtD
Methylnaltrexone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000866	0.00459	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000846	0.00448	CcSEcCtD
Methylnaltrexone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000838	0.00444	CcSEcCtD
Methylnaltrexone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000833	0.00442	CcSEcCtD
Methylnaltrexone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000833	0.00441	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000832	0.00441	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000807	0.00428	CcSEcCtD
Methylnaltrexone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000805	0.00427	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000805	0.00426	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000801	0.00425	CcSEcCtD
Methylnaltrexone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000799	0.00424	CcSEcCtD
Methylnaltrexone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000787	0.00417	CcSEcCtD
Methylnaltrexone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000778	0.00412	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000777	0.0222	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000775	0.0041	CcSEcCtD
Methylnaltrexone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000774	0.0041	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000764	0.00405	CcSEcCtD
Methylnaltrexone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000761	0.00403	CcSEcCtD
Methylnaltrexone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000753	0.00399	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000739	0.00392	CcSEcCtD
Methylnaltrexone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000732	0.00388	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00073	0.0209	CbGpPWpGaD
Methylnaltrexone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000728	0.00386	CcSEcCtD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000724	0.0207	CbGpPWpGaD
Methylnaltrexone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000723	0.00383	CcSEcCtD
Methylnaltrexone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.0007	0.00371	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000697	0.00369	CcSEcCtD
Methylnaltrexone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000683	0.00362	CcSEcCtD
Methylnaltrexone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000673	0.00357	CcSEcCtD
Methylnaltrexone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00067	0.00355	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000657	0.0188	CbGpPWpGaD
Methylnaltrexone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000654	0.00347	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000654	0.0187	CbGpPWpGaD
Methylnaltrexone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000648	0.00343	CcSEcCtD
Methylnaltrexone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000647	0.00343	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.00064	0.00339	CcSEcCtD
Methylnaltrexone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000623	0.0033	CcSEcCtD
Methylnaltrexone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000618	0.00328	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000617	0.0176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000612	0.0175	CbGpPWpGaD
Methylnaltrexone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000605	0.0032	CcSEcCtD
Methylnaltrexone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000594	0.00315	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000591	0.0169	CbGpPWpGaD
Methylnaltrexone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000582	0.00308	CcSEcCtD
Methylnaltrexone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000555	0.00294	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000553	0.0158	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000551	0.0158	CbGpPWpGaD
Methylnaltrexone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000544	0.0833	CbGeAlD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000539	0.0154	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000539	0.0154	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000524	0.015	CbGpPWpGaD
Methylnaltrexone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000524	0.0802	CbGeAlD
Methylnaltrexone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000522	0.0798	CbGeAlD
Methylnaltrexone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000501	0.0143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0005	0.0143	CbGpPWpGaD
Methylnaltrexone—OPRM1—blood—acquired immunodeficiency syndrome	0.000477	0.073	CbGeAlD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000466	0.0133	CbGpPWpGaD
Methylnaltrexone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000459	0.0703	CbGeAlD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000439	0.0125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000423	0.0121	CbGpPWpGaD
Methylnaltrexone—OPRK1—brain—acquired immunodeficiency syndrome	0.000416	0.0636	CbGeAlD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000404	0.0115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000397	0.0113	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000396	0.0113	CbGpPWpGaD
Methylnaltrexone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000387	0.0592	CbGeAlD
Methylnaltrexone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000373	0.057	CbGeAlD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000371	0.0106	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000365	0.0104	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000362	0.0103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000343	0.00982	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000343	0.00982	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000341	0.00976	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000335	0.00958	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000334	0.00955	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000309	0.00882	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000308	0.00881	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000302	0.00863	CbGpPWpGaD
Methylnaltrexone—OPRM1—brain—acquired immunodeficiency syndrome	0.000296	0.0453	CbGeAlD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00029	0.0083	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00029	0.0083	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00029	0.00828	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00029	0.00828	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000286	0.00817	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000283	0.00809	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000282	0.00807	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000271	0.00774	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000269	0.00769	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000261	0.00747	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00026	0.00744	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000255	0.0073	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000245	0.007	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000245	0.007	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000245	0.007	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000242	0.00691	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000239	0.00683	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000235	0.00673	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00023	0.00658	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00023	0.00658	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000229	0.00655	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000227	0.0065	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000227	0.00649	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000221	0.00631	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00022	0.0063	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000207	0.00592	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000206	0.0059	CbGpPWpGaD
Methylnaltrexone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000201	0.0307	CbGeAlD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000199	0.00569	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000199	0.00568	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000195	0.00557	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000195	0.00557	CbGpPWpGaD
Methylnaltrexone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000191	0.0293	CbGeAlD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000187	0.00533	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000186	0.00532	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000184	0.00527	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000175	0.00501	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000175	0.00501	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000175	0.00501	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000174	0.00498	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000171	0.0049	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000168	0.0048	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000167	0.00478	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000158	0.00451	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000158	0.00451	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000156	0.00445	CbGpPWpGaD
Methylnaltrexone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000155	0.0237	CbGeAlD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000155	0.00443	CbGpPWpGaD
Methylnaltrexone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000149	0.0229	CbGeAlD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000148	0.00424	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000148	0.00424	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000148	0.00423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000145	0.00414	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000141	0.00404	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000133	0.00381	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000133	0.00381	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000131	0.00374	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000123	0.00351	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00012	0.00344	CbGpPWpGaD
Methylnaltrexone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000119	0.0182	CbGeAlD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000113	0.00322	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000106	0.00303	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000105	0.00301	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000102	0.0029	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000101	0.00289	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000101	0.00289	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.92e-05	0.00283	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.92e-05	0.00283	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.58e-05	0.00274	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.16e-05	0.00262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9e-05	0.00257	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9e-05	0.00257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.95e-05	0.00256	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.91e-05	0.00255	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.56e-05	0.00245	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.56e-05	0.00245	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.38e-05	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.38e-05	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.09e-05	0.00231	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.74e-05	0.00221	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.61e-05	0.00217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.61e-05	0.00217	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.54e-05	0.00216	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.43e-05	0.00212	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.85e-05	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.8e-05	0.00194	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.75e-05	0.00193	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	6.66e-05	0.0019	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.38e-05	0.00182	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.28e-05	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.26e-05	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.17e-05	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.79e-05	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.74e-05	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.7e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	5.66e-05	0.00162	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.66e-05	0.00162	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.32e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.32e-05	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.29e-05	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.22e-05	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.78e-05	0.00137	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.5e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.5e-05	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.05e-05	0.00116	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.99e-05	0.00114	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.93e-05	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.65e-05	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.57e-05	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.000977	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.000963	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.32e-05	0.000948	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.000881	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.01e-05	0.000861	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.11e-05	0.000602	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000599	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000509	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.77e-05	0.000506	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.24e-05	0.000354	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.16e-05	0.000332	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000299	CbGpPWpGaD
